Despite early signs of on-target pharmacological activity, Septerna has decided to focus on advancing next-generation PTH1R agonists with distinct chemical structures. Jeffrey Finer, CEO and co ...
SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of ...
SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two ...
Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback